Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up

Mary K. Interrante(Georgetown University), Mark D. Schwartz(New York University), Judy E. Garber(Dana-Farber Cancer Institute), Rachel Nusbaum(Icahn School of Medicine at Mount Sinai), Marie Wood(University of Colorado Cancer Center), Gillian W. Hooker(National Institutes of Health), Tiffani A. DeMarco(Georgetown University), Hannah Segal(Georgetown University), Shelley R. McCormick(Georgetown University), Claudine Isaacs(Georgetown University), Kristi D. Graves(Georgetown University), Heiðdís Valdimarsdóttir(Reykjavík University), Jessica Heinzmann(Atlantic Health System), Morgan Similuk, Anita Y. Kinney(Georgetown University), Wendy McKinnon(University of Vermont), Beth N. Peshkin(Georgetown University)
JNCI Cancer Spectrum
September 1, 2017
10.1093/jncics/pkx002
Cited by 19

Related Papers

Mutational Processes Molding the Genomes of 21 Breast Cancers
|Cell|2012|2k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k